anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Heart failure (HF) remains a major medical and social problem. The NT-pro-brain natriuretic peptide (NT-proBNP) and its active form, brain-type natriuretic peptide (BNP), in a simple blood test are the gold-standard biomarkers for HF diagnosis. However, even good biomarkers such as natriuretic peptides fail to predict all the risks associated with HF due to the diversity of the mechanisms involved. The pathophysiology of HF is determined by numerous factors, including oxidative stress, inflammation, neuroendocrine activation, pathological angiogenesis, changes in apoptotic pathways, fibrosis and vascular remodeling. High readmission and mortality rates prompt a search for new markers for the diagnosis, prognosis and treatment of HF. Oxidative-stress-mediated inflammation plays a crucial role in the development of subsequent changes in the failing heart and provides a new insight into this complex mechanism. Oxidative stress and inflammatory biomarkers appear to be a promising diagnostic and prognostic tool in patients with HF. This systematic review provides an overview of the current knowledge about oxidative stress and inflammation parameters as markers of HF.
INTRODUCTION: Obese patients often have higher complication rates after elective general surgeries; however, few studies have examined the outcomes after thyroidectomy. This study examines whether increased body mass index (BMI) is associated with poor postoperative outcomes after thyroid surgery.
METHODS: A retrospective review of patients who underwent thyroidectomy from 2015 to 2018 was performed. Demographics, comorbidities, pathology, and extent of resection (total versus hemithyroidectomy) were examined. Patients were classified into BMI groups according to the WHO definitions, and the incidence of surgical outcomes was determined in each group. Surgical outcomes of interest included readmission rates (RRs), length of stay, average operating room time, return to the operating room, hypocalcemia, postop infections, hematomas, and recurrent laryngeal nerve injury. Between-subjects statistics including independent samples t-test, ANOVA, and chi-square analyses were performed.
RESULTS: There were n = 465 patients included with a mean BMI 32.35 (standard deviation = 8.55) and median BMI 30.78 (Q1 = 26.26, Q3 = 36.73). There were no differences between BMI groups in age, gender, smoking, heart disease. There was a positive association between increased BMI and postoperative infection (P < 0.001), pneumonia (P = 0.018), and surgical site infection (P = 0.04), which were highest for BMI > 40. Increased BMI was associated with a higher 30-d RR (P = 0.008), particularly for BMI >40 versus BMI <40 (6.2% versus 1.05%; P = 0.003). There were no significant differences between surgical outcomes for patients with increased BMI who underwent total thyroidectomy or hemithyroidectomy.
CONCLUSIONS: Excellent postoperative outcomes were observed in all BMI categories. Higher postoperative infection and 30-d RRs were observed in the morbidly obese. Contrary to previous studies, operating room times were similar regardless of BMI.
Why do we move slower as we grow older? The reward circuits of the brain, which tend to invigorate movements, decline with aging, raising the possibility that reduced vigor is due to the diminishing value that our brain assigns to movements. However, as we grow older, it also becomes more effortful to make movements. Is age-related slowing principally a consequence of increased effort costs from the muscles, or reduced valuation of reward by the brain? Here, we first quantified the cost of reaching via metabolic energy expenditure in human participants (male and female), and found that older adults consumed more energy than the young at a given speed. Thus, movements are objectively more costly for older adults. Next, we observed that when reward increased, older adults, like the young, responded by initiating their movements earlier. Yet, unlike the young, they were unwilling to increase their movement speed. Was their reluctance to reach quicker for rewards due to the increased effort costs, or because they ascribed less value to the movement? Motivated by a mathematical model, we next made the young experience a component of aging by making their movements more effortful. Now the young responded to reward by reacting faster but chose not to increase their movement speed. This suggests that slower movements in older adults are partly driven by an adaptive response to an elevated effort landscape. Moving slower may be a rational economic response the brain is making to mitigate the elevated effort costs that accompany aging.
Context. The emergence of new problematic alcohol consumption practices among young people requires new dynamics in prevention strategies. In this context, the ADUC project (Alcohol and Drugs at the University of Caen) aims to develop a better understanding of alcohol consumption, and in particular the practice of binge drinking (BD), in order to develop relevant and adapted prevention tools. The first step, logistically supported by the University of Caen, consisted in identifying the levels of alcohol consumption of students, the prevalence of binge drinking, and their determinants. Based on more than 7000 participants interviewed, it essentially demonstrated 1) an alarming 22% prevalence of BD among students and 2) three main psychological determinants (see Mange et al., 2021), namely subjective norm (i.e., perception of what is done and/or approved by peers), drinker identity (i.e., how the individual defines him/herself as a drinker), and motivations to drink (social, compliance, enhancement, or coping motivations). Objective. The ALCOMEDIIT study (IRESP funding; Agreement 20II31-00

- ADUC part 3) is a randomized controlled trial . The main objective of this experiment in social psychology is to validate three programs for the prevention of BD practices based on motivational interviewing (MI) associated either induced hypocrisy (IH), social identity mapping (SIM) and motivational modeling (MM) in a student environment..

Materials and Methods. This study will include 240 healthy subjects who will be students at the University of Caen Normandy. They will be people who consume alcohol, having a BD score \> 1 in the month preceding the inclusion but not presenting any specific disorder. The trial will be proposed to them by e-mail and the people who meet the inclusion criteria will join either a control group which will benefit from a MI, or an experimental group which will also benefit from a MI but which will be associated with one out of our three psycho-social interventions (IH vs. SIm vs. MM). In order to measure the effectiveness of each prevention program in terms of reducing the use of BD, a follow-up at 1 month (T1) as well as a follow-up at 6 months (T6; exploratory) will be proposed to all participants. The total duration of this research protocol is almost two years. Hypothesis tested. The aim of this work is to evaluate the interest of associating IH, SIM or MM with a motivational interview in a prevention program aiming at reducing alcohol use and the practice of BD in the student population.
The present invention relates to an externally-applied medicinal liquor for treating condyloma acuminatum and a preparation method thereof. Each 120 ml of the medicinal liquor contains 60 to 80% of ethanol and the effective ingredients of the following raw medicines: 7 to 11g of khosam, 4 to 8g of clove, 4 to 8g of realgar, 2 to 5g of Chinese gall, 4 to 8g of red halloysite and balance of water. An alcohol immersion method and a traditional Chinese medicine decoction method are adopted, and the preparation method is simple. The medicine has the characteristics of especially good effect, obvious effect, high safety, convenient use, short course of treatment, no relapse and no special toxic or side effect. The cure rate by one application can reach 100%. The medicine has an especially good effect on treating condyloma acuminatum clinically at present.
BACKGROUND: The crucial role of inflammation in aortic aneurysm (AA) is gaining prominence, while there is still a lack of key cytokines or targets for effective clinical translation.
METHODS: Mendelian randomization (MR) analysis was performed to identify the causal relationship between 91 circulating inflammatory proteins and AA and between 731 immune traits and AA. Bulk RNA sequencing data was utilized to demonstrate the expression profile of the paired ligand-receptor. Gene enrichment analysis, Immune infiltration, and correlation analysis were employed to deduce the potential role of CX3CR1. We used single-cell RNA sequencing data to pinpoint the localization of CX3CL1 and CX3CR1, which was further validated by multiplex immunofluorescence staining. Cellchat analysis was utilized to infer the CX3C signaling pathway. Trajectory analysis and the Cytosig database were exploited to determine the downstream effect of CX3CL1-CX3CR1.
RESULTS: We identified 4 candidates (FGF5, CX3CL1, IL20RA, and SCF) in multiple two-sample MR analyses. Subsequent analysis of the expression profile of the paired receptor revealed the significant upregulation of CX3CR1 in AA and its positive correlation with pro-inflammatory macrophages. Two sample MR between immune cell traits and AA demonstrated the potential causality between intermediate monocytes and AA. We finally deciphered in single-cell sequencing data that CX3CL1 sent by endothelial cells (ECs) acted on CX3CR1 of intermediated monocytes, leading to its recruitment and pro-inflammatory responses.
CONCLUSION: Our study presented a genetic insight into the pathogenetic role of CX3CL1-CX3CR1 in AA, and further deciphered the CX3C signaling pathway between ECs and intermediate monocytes.
Normal Saline (placebo) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
The invention discloses a traditional Chinese medicine for treating leucoderma by oral administration and washout, and belongs to the technical field of a traditional Chinese medicine. The internal medicine is prepared from the following crude drugs: rehmannia glutinosa libosch, radix angelicae, fructus psoraleae, radix curcumae longae, rhizoma smilacis glabrae, radix bupleuri, rhizoma atractylodis, schizonepeta, glossy privet fruit, caulis spatholobi, prepared fleece flower root, root bark of the peony tree, fruit of Chinese wolfberry, angelica sinensis, herba epimedii, root of red-rooted salvia, uncaria, golden cypress, tuber fleeceflower stem, peach kernel, flowers carthami and liquorice. The washout medicine is prepared from the following raw materials: schizonepeta, almond, alum, mint, angelica sinensis, radix angelicae, radices sileris, fructus forsythia, rhizoma smilacis glabrae, polygonum multiflorum, root of common peony, radix sophorae flavescentis and borneol. The internal medicine disclosed by the invention has the effects of warming meridians, dredging qi and blood, clearing away heat and toxic materials, promoting blood circulation to remove blood stasis and the like. The external medicine can directly act on skin of the affected part and remove vitiligo, so as to roundly inhibit and effectively cure leucoderma. Thus, the target of complete recovery is achieved.
(1) Background: With the increasing aesthetic pursuit of facial features, the clinical use of Botulinum Toxin Type A (BoNT-A) injections for masseter hypertrophy has been on the rise. However, due to variations in masseter muscle structure and differences in clinicians' injection techniques, blind injections may lack precision, potentially compromising treatment accuracy and increasing the risk of complications. (2) Objectives: The study aims to use ultrasonography to detail the deep inferior tendon (DIT) within the masseter muscle in a young Chinese cohort, refine its classification, analyze muscle belly thickness and variations across groups, and propose a customized ultrasound-guided BoNT-A injection protocol. (3) Methods: Ultrasound imaging was used to observe the bilateral masseter muscles at rest and during clenching. The features of the DIT were classified from these images, and the thickness of the masseter's distinct bellies associated with the DIT types was measured in both states. (4) Results: The study cohort included 103 participants (27 male, 76 female), with 30 muscles in the normal masseter group and 176 muscles in the hypertrophy group. The DIT was categorized as Type A, B (subtypes B1, B2), and C. The distribution of these types was consistent across normal, hypertrophic, and gender groups, all following the same trend (B > A > C). In hypertrophy, Type B1 showed uniform thickness across masseter bellies, B2 presented with a thinner intermediate belly, and Type C had mainly superficial muscle enlargement. Changes in muscle thickness during clenching were noted but not statistically significant among different bellies. (5) Conclusions: The study evidences individual variation in the DIT, highlighting the importance of precise DIT classification for effective BoNT-A injections. A tailored ultrasound-guided BoNT-A injection strategy based on this classification may enhance safety and efficacy of the therapy.
OBJECTIVE: Laparoscopic sleeve gastrectomy (LSG) is a widely recognized effective bariatric surgery. However, variable weight loss outcomes post-surgery remained a clinical challenge. Currently, there is no established consensus on the factors influencing weight loss failure following LSG. This study aimed to explore the association between preoperative cortisol secretion autonomy and postoperative weight loss in obese patients undergoing LSG.
PATIENTS AND METHODS: A cohort of 181 patients with simple obesity (BMI ≥ 28 kg/m2) who underwent LSG and were followed up for one year was analyzed. Weight loss was measured by the percentage of excess weight loss (%EWL), and cortisol secretion autonomy was evaluated using a 1 mg dexamethasone suppression test (DST). Regression models were used to analyze the correlation between preoperative 1 mg DST results and %EWL one year after laparoscopic sleeve gastrectomy (LSG).
RESULTS: Cortisol secretion autonomy was significantly lower in the %EWL ≥ 75% group and higher in the %EWL < 75% group, showing a negative correlation with %EWL (R = -0.336, p = 0.001). Logistic regression analysis indicated that high cortisol secretion autonomy was significantly correlated with %EWL < 75% after LSG. The likelihood of %EWL being < 75% was 10.47 times greater in patients with high cortisol secretion autonomy compared to those with low cortisol secretion autonomy (odds ratio 10.472, confidence interval: 1.660-66.048, p = 0.012).
CONCLUSIONS: Cortisol secretion autonomy emerges as an independent predictor of weight loss outcomes in Asian patients undergoing LSG. This finding suggests the potential for cortisol secretion autonomy to inform preoperative assessments and personalized treatment strategies in bariatric surgery.
Participants diagnosed with Arterial Calcifications due to Deficiency in CD73 (ACDC) will receive Etidronate. Etidronate will be administered orally at total dose of 20mg/kg daily x 14 days, followed by 10 weeks off study drug (12 weeks = one cycle). Participants may receive up to 12 cycles of etidronate.
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics. What is created is an immunologically relevant composition inducing an immune response on at least two strains and/or serotypes Streptococcus uberis, containing at least one recovered and/or recombinant protein having a specific amino acid sequence prepared by the method involving transformation of prokaryotic and eukaryotic cells or a microorganism, such as a bacterium, yeast, or fungi, by a nucleic acid construct coding the above protein, a recombinant nucleic acid molecule, a recombinant carrier and/or their immunologically relevant portion, derivative and/or analogue. A method for preparing the immunologically relevant composition. A method for identifying a protein of the bacterium Streptococcus uberis, that induces the immune response to at least two strains and/or serotypes Streptococcus uberis, involving the stages: a) identifying at least a portion of the secreted protein, superficially associated protein and/or protein min. 80% identical to a sequence of the bacterial virulence factor, b) selecting at least one protein identified at the stage a), which persists in at least two strains and/or serotypes Streptococcus uberis, c) determining an ability of at least one protein selected at the stage b) or its immunologically relevant portion, derivative or analogue to bind specifically the antibody and/or immune cells of an animal infected with the first strain and/or serotype Streptococcus uberis, and the antibody and/or immune cells of an animal infected with the second strain and/or serotype Streptococcus uberis. A method for inducing the immune response on at least two strains and/or serotypes Streptococcus uberis. And also a bovine mastitis diagnostic kit containing at least one protein having the specific amino acid sequence, the recombinant nucleic acid molecule, the recombinant carrier and the agents for detecting the antibodies.EFFECT: using the invention enables inducing the immune response on at least two strains and/or serotypes Streptococcus uberis.21 cl, 4 dwg, 7 tbl, 12 ex
The present invention provides burn treating powder which belongs to the technical field of traditional Chinese medicine. The powder is mainly used for treating burns and scalds with the area of 30% of a deep II degree. The powder is processed and prepared from the traditional Chinese medicine of coptis, phellodendron bark, rhubarb, sanguisorba roots, Chinese angelica, puff balls, alkanna tinctoria, carbonized hair, pearl powder, borneol, licorice roots, etc. After the powder is coated on skin of affected parts, dressing is not required to be used for packing. The exogenous pollution of bacteria can be thoroughly isolated and stopped by explosion treatment. In addition, the powder has the advantages of rapid pain alleviation, strong antibiotic capability, treatment time a reduction and medical cost saving. Patients have no pain caused by dressing exchange during dressing change. When the powder is used for treating burns and scalds particularly, no scar remains after cure, and the physiological function of a joint is maintained.
Subjects who provide written informed consent to participate voluntarily in the clinical study will be screened. Eligible subjects will be sequentially enrolled into the above five sequential cohorts and randomized to receive PL-18 (cohort 1: n=8; cohort 2/3/4/5: n=6) or matching placebo (n=2). Subjects will be observed for 3 days after a single dose and receive PL-18 or placebo, once daily, for 6 consecutive days, if no grade ≥2 drug-related adverse events (AEs) occur. During the study, PK sample collection, physical examination, vital signs, laboratory tests, electrocardiography (ECG) and tolerance evaluation will be performed based on the protocol schedule.

To ensure the safety of the subjects, two sentinel subjects will be enrolled first in each cohort; one subject will be randomized to receive PL-18, and the other subject randomized to receive placebo. The safety data of the two sentinel subjects from initiation of single dosing to the last drug administration of multiple dosing on D11 will be reviewed by the investigator and sponsor before the subsequent subjects in that dose cohort are enrolled. Subsequent subjects could be simultaneously enrolled, with one randomized to receive placebo and others randomized to receive PL-18.
The present invention relates to an antibacterial composition including a fermented extract of Raphanus sativus L. var. niger or a fraction thereof. The fermented extract of Raphanus sativus L. var. niger and fraction thereof has an excellent antibacterial effect against the strains of Staphylococcus epidermidis and Propionibacterium acnes causing acne. In addition, the extract of Raphanus sativus L. var. niger and fraction thereof shows an antibacterial effect against Staphylococcus epidermidis and Propionibacterium acnes having resistance against erythromycin, and thus can be used for an antibacterial composition, particularly, a cosmetic composition, and for a pharmaceutical composition, health-aid food composition and cosmetic composition for alleviating or treating acne.
The invention discloses a small molecular peptide and application thereof in inhibiting xanthine oxidase, and belongs to the technical field of enzymolysis processing products. The amino acid sequence of the small molecule peptide is shown as SEQ ID NO. 2. The application of the small molecular peptide in preparing medicines for inhibiting xanthine oxidase and medicines for inhibiting uric acid level is provided. The invention obtains the small molecular peptide with high inhibition activity to xanthine oxidase through experimental study and screening. The invention has important significance for treating hyperuricemia.
Tenofovir disoproxil fumarate (TDF) (a prodrug of tenofovir) which is a fumaric acid salt of bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir. TDF is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Tenofovir exhibits activity against HIV-1 reverse transcriptase. 

The chemical name of TDF is 9-[(R)-2-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl] adenine fumarate (1:1). It has a molecular formula of C 19H 30N 5O 10P • C 4H 4O 4 and a molecular weight of 635.52. It has the following structural formula:   


  


Tenofovir disoproxil fumarate is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in distilled water at 25°C. It has an octanol/phosphate buffer (pH 6.5) partition coefficient (log p) of 1.25 at 25 °C.   
Tenofovir disoproxil fumarate is available as tablets.   
Tenofovir disoproxil fumarate tablets are for oral administration. Each tablet contains 300 mg of TDF, which is equivalent to 245 mg of tenofovir disoproxil. Each tablet contains the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose and pregelatinized starch. The 300 mg tablets are coated with opadry II white which contains hypromellose, lactose monohydrate, titanium dioxide and triacetin.   
In this insert, all dosages are expressed in terms of TDF except where otherwise noted.
The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles.